Cardiovascular Disease

Evolocumab Cuts First Cardiovascular Events by 31% in High‑Risk Diabetes Without Known Atherosclerosis

The ACC 2026 analysis signals earlier, more aggressive LDL cholesterol lowering could reshape primary prevention for patients with diabetes.